169 related articles for article (PubMed ID: 25279503)
41. HIV-1 TAT-mediated microglial activation: role of mitochondrial dysfunction and defective mitophagy.
Thangaraj A; Periyasamy P; Liao K; Bendi VS; Callen S; Pendyala G; Buch S
Autophagy; 2018; 14(9):1596-1619. PubMed ID: 29966509
[TBL] [Abstract][Full Text] [Related]
42. TGF-β1 stimulates mitochondrial oxidative phosphorylation and generation of reactive oxygen species in cultured mouse podocytes, mediated in part by the mTOR pathway.
Abe Y; Sakairi T; Beeson C; Kopp JB
Am J Physiol Renal Physiol; 2013 Nov; 305(10):F1477-90. PubMed ID: 24049142
[TBL] [Abstract][Full Text] [Related]
43. Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.
Wright TM; Wardell SE; Jasper JS; Stice JP; Safi R; Nelson ER; McDonnell DP
Mol Cancer Res; 2014 Dec; 12(12):1829-39. PubMed ID: 25100862
[TBL] [Abstract][Full Text] [Related]
44. Influence of oestradiol and tamoxifen on oestrogen receptors-alpha and -beta protein degradation and non-genomic signalling pathways in uterine and breast carcinoma cells.
Horner-Glister E; Maleki-Dizaji M; Guerin CJ; Johnson SM; Styles J; White IN
J Mol Endocrinol; 2005 Dec; 35(3):421-32. PubMed ID: 16326830
[TBL] [Abstract][Full Text] [Related]
45. Estrogen-dependent and independent activation of the P1 promoter of the p53 gene in transiently transfected breast cancer cells.
Hurd C; Dinda S; Khattree N; Moudgil VK
Oncogene; 1999 Jan; 18(4):1067-72. PubMed ID: 10023683
[TBL] [Abstract][Full Text] [Related]
46. Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines.
Kim J; Lee J; Jang SY; Kim C; Choi Y; Kim A
Oncol Rep; 2016 May; 35(5):2553-60. PubMed ID: 26986571
[TBL] [Abstract][Full Text] [Related]
47. GGNBP2 acts as a tumor suppressor by inhibiting estrogen receptor α activity in breast cancer cells.
Lan ZJ; Hu Y; Zhang S; Li X; Zhou H; Ding J; Klinge CM; Radde BN; Cooney AJ; Zhang J; Lei Z
Breast Cancer Res Treat; 2016 Jul; 158(2):263-76. PubMed ID: 27357812
[TBL] [Abstract][Full Text] [Related]
48. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
[TBL] [Abstract][Full Text] [Related]
49. Identification of novel proteins induced by estradiol, 4-hydroxytamoxifen and acolbifene in T47D breast cancer cells.
Al-Dhaheri MH; Shah YM; Basrur V; Pind S; Rowan BG
Steroids; 2006 Nov; 71(11-12):966-78. PubMed ID: 16949628
[TBL] [Abstract][Full Text] [Related]
50. Lipidome and metabolome analyses reveal metabolic alterations associated with MCF-7 apoptosis upon 4-hydroxytamoxifen treatment.
Nishimoto K; Okahashi N; Maruyama M; Izumi Y; Nakatani K; Ito Y; Iida J; Bamba T; Matsuda F
Sci Rep; 2023 Oct; 13(1):18549. PubMed ID: 37899460
[TBL] [Abstract][Full Text] [Related]
51. Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.
Maximov PY; McDaniel RE; Fernandes DJ; Bhatta P; Korostyshevskiy VR; Curpan RF; Jordan VC
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25258390
[TBL] [Abstract][Full Text] [Related]
52. Modulation of mitochondrial bioenergetics in a skeletal muscle cell line model of mitochondrial toxicity.
Dott W; Mistry P; Wright J; Cain K; Herbert KE
Redox Biol; 2014; 2():224-33. PubMed ID: 24494197
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of T47D human breast cancer cell growth by the synthetic progestin R5020: effects of serum, estradiol, insulin, and EGF.
Gill PG; Tilley WD; De Young NJ; Lensink IL; Dixon PD; Horsfall DJ
Breast Cancer Res Treat; 1991 Dec; 20(1):53-62. PubMed ID: 1813069
[TBL] [Abstract][Full Text] [Related]
54. Tamoxifen metabolite endoxifen interferes with the polyamine pathway in breast cancer.
Thomas TJ; Thomas T; John S; Hsu HC; Yang P; Keinänen TA; Hyvönen MT
Amino Acids; 2016 Oct; 48(10):2293-302. PubMed ID: 27438264
[TBL] [Abstract][Full Text] [Related]
55. Role of mitochondrial function in the invasiveness of human colon cancer cells.
Lin CS; Liu LT; Ou LH; Pan SC; Lin CI; Wei YH
Oncol Rep; 2018 Jan; 39(1):316-330. PubMed ID: 29138850
[TBL] [Abstract][Full Text] [Related]
56. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation.
Chan CM; Martin LA; Johnston SR; Ali S; Dowsett M
J Steroid Biochem Mol Biol; 2002 Aug; 81(4-5):333-41. PubMed ID: 12361723
[TBL] [Abstract][Full Text] [Related]
57. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
Gaddy VT; Barrett JT; Delk JN; Kallab AM; Porter AG; Schoenlein PV
Clin Cancer Res; 2004 Aug; 10(15):5215-25. PubMed ID: 15297425
[TBL] [Abstract][Full Text] [Related]
58. Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance.
Pitta CA; Papageorgis P; Charalambous C; Constantinou AI
Cancer Lett; 2013 Sep; 337(2):167-76. PubMed ID: 23752064
[TBL] [Abstract][Full Text] [Related]
59. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells.
Fox EM; Bernaciak TM; Wen J; Weaver AM; Shupnik MA; Silva CM
Mol Endocrinol; 2008 Aug; 22(8):1781-96. PubMed ID: 18550772
[TBL] [Abstract][Full Text] [Related]
60. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
